10/7/2019
`
`Expert Opinion on Drug Delivery
`
`Journal
`
`Expert Opinion on Drug Delivery >
`
`This
`
`Instructions for authors
`
`Thank you for choosing to submit your paper to us. These instructions will ensure we have
`
`everything required so your paper can move through peer review, production and
`
`publication smoothly. Please take the time to read and follow them as closely as possible,
`
`as doing so will ensure your paper matches the journal's requirements.
`
`AUTHORSERVICES
`
`Supporting Taylor & Francis autriers
`
`For general guidance on every stage of the publication process, please visit our Author
`
`Services website.
`
`EDITINGSERVICES
`
`Supporting Taylor & Francis authors
`
`For editing support, including translation and language polishing, explore our Editing
`
`Services website
`soi0LARONE MANUSCRIPTS -
`
`This journal uses ScholarOne Manuscripts (previously Manuscript Central) to peer review
`
`manuscript submissions. Please read the guide for ScholarOne authors before making a
`
`submission. Complete guidelines for preparing and submitting your manuscript to this
`
`journal are provided below.
`
`Contents list
`
`• About the journal
`
`https://www.tandfonline.com/action/authorSubmission?journalCode=iedd20&page=instructions&
`
`•
`
`Da
`
`Rptr.
`
`1
`Bi4
`012_4
`7r„
`A
`e-A
`,ff
`Depo e
`
`te __e___
`/
`4
`WWW.DEPOBOOKPRODUCTS.CO
`
`•
`
`1/13
`
`Sanofi Exhibit 2224.001
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`Expert Opinion on Drug Delivery
`
`10/7/2019
`
`• Peer review
`
`• Preparing your paper
`
`• Guidelines by article type
`
`• Formatting
`
`• References
`
`• Checklist
`
`• Using third-party material in your paper
`
`• Financial and competing interests disclosure
`
`• Clinical Trials Registry
`
`• Complying with ethics of experimentation
`
`• Consent
`
`• Health and safety
`
`• Submitting your paper
`
`• Data Sharing Policy
`
`• Publication charges
`
`• FastTrack and RapidTrack publication
`
`• Copyright options
`
`• Complying with funding agencies
`
`• Accepted Author Version (AAV)
`
`• My Authored Works
`
`• Article reprints
`
`About the journal
`
`Expert Opinion on Drug Delivery is an international, peer-reviewed journal publishing high-
`
`quality, review articles, original research, editorials and drug evaluation articles on drug
`
`delivery. Please see the journal's Aims & Scope for information about its focus and peer-
`
`review policy.
`
`Please note that this journal only publishes manuscripts in English.
`
`Peer review
`
`Taylor & Francis is committed to peer-review integrity and upholding the highest standards
`
`of review. Once your paper has been assessed for suitability by the editor, it will then be
`
`https://www.tandfonline.com/action/authorSubmission?journalCode=iedd20&page=instructions&
`
`2/13
`
`Sanofi Exhibit 2224.002
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`10/7/2019
`
`Expert Opinion on Drug Delivery
`
`double blind peer-reviewed by independent, anonymous expert referees. Find out more
`
`about what to expect during peer review and read our guidance on publishing ethics.
`
`Preparing your paper
`
`All authors submitting to medicine, biomedicine, health sciences, allied and public health
`
`journals should conform to the Uniform Requirements for Manuscripts Submitted to
`
`Biomedical Journals, prepared by the International Committee of Medical Journal Editors
`
`(ICMJE).
`
`Guidelines by article type
`
`This journal publishes the following article types. Please follow the links to view the
`
`guidelines for each article type. You can also visit the Expert Collection page on our Author
`
`Services website.
`
`• Review Article
`
`• Original Research
`
`• Technology Evaluation
`
`• Key Paper Evaluation
`
`• Meta-opinion
`
`• Meeting Report
`
`• Letter to the Editor
`
`• Editorial
`
`Formatting
`
`Papers should be submitted in Word format.
`
`File formatting: Keep all formatting to a minimum. Do not assign 'styles' to headings,
`
`extracts or paragraphs. Make sure that the 'normal' style is used throughout the text. Turn
`
`off the automatic hyphenation feature.
`
`Spacing and headings: Headings, sub-headings and title paragraphs should be used to
`
`divide the text. Please use numbers (Arabic numerals) to indicate a hierarchy of
`
`headings/sub-headings (i.e., 1.0, 1.1, 2.0, 2.1, 2.1.1, 2.1.2 and so on).
`
`https://www.tandfonline.com/action/authorSubmission?journalCode=iedd20&page=instructions&
`
`3/13
`
`Sanofi Exhibit 2224.003
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`10/7/2019
`
`Expert Opinion on Drug Delivery
`
`Spelling: All articles will be published in American English. Authors are advised to check
`
`their work for English spelling and grammar prior to submission. The Editorial Office can
`
`assist with the process of preparing and submitting a manuscript with Taylor & Francis
`
`Editing Services, offering authors: English language editing, translation (from Chinese,
`
`Spanish, Portuguese or Japanese into English), manuscript formatting and figure
`
`preparation.
`
`Please see our formatting guide for full instructions.
`
`If you are not able to use the template via the links (or if you have any other template
`
`queries) please contact us here.
`
`References
`
`Please use this reference guide when preparing your paper. An EndNote output style is also
`
`available to assist you.
`
`Papers or patents of particular interest should be identified using one or two asterisk
`
`symbols (* = of interest, ** = of considerable interest), and annotated with a brief sentence
`
`explaining why the reference is considered to be of interest.
`
`Checklist: what to include
`
`1. Author details. Please ensure everyone meeting the International Committee of Medical
`
`Journal Editors (ICJME) requirements for authorship is included as an author of your paper.
`
`All authors of a manuscript should include their full name and affiliation on the cover page
`
`of the manuscript. Where available, please also include ORCiDs and social media handles
`
`(Facebook, Twitter or Linkedln). One author will need to be identified as the corresponding
`
`author, with their email address normally displayed in the article PDF (depending on the
`
`journal) and the online article. Authors' affiliations are the affiliations where the research
`
`was conducted. If any of the named co-authors moves affiliation during the peer-review
`
`process, the new affiliation can be given as a footnote. Please note that no changes to
`
`affiliation can be made after your paper is accepted. Read more on authorship.
`
`A structured abstract should cover (in the following order) .
`
`3. A structured abstract of no more than 200 words. A structured abstract should cover (in
`
`the following order):
`
`https://www.tandfonline.com/action/authorSubmission?journalCode=iedd20&page=instructions&
`
`4/1 3
`
`Sanofi Exhibit 2224.004
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`10/7/2019
`
`Expert Opinion on Drug Delivery
`
`o
`
`Introduction: Authors are required to describe the significance of the topic under
`
`discussion.
`
`o Areas covered: Authors are required to describe the research discussed and the
`
`literature search undertaken.
`
`O Expert Opinion/Commentary: Authors are required to summarise briefly their Expert
`
`Opinion/Commentary section.
`
`References must not be included in the abstract.
`
`Read tips on writing your abstract.
`
`4. You can opt to include a video abstract with your article. Find out how these can help your
`
`work reach a wider audience, and what to think about when filming.
`
`5. 5-8 keywords. Read making your article more discoverable, including information on
`
`choosing a title and search engine optimization.
`
`6. Funding details. Please supply all details required by your funding and grant-awarding
`
`bodies as follows: For single agency grants This work was supported by the [Funding
`
`Agency] under Grant [number xxxx]. For multiple agency grants: This work was supported
`
`by the [Funding Agency 1]; under Grant [number xxxx]; [Funding Agency 2] under Grant
`
`[number xxxx]; and [Funding Agency 3] under Grant [number xxxx].
`
`7. Disclosure statement. This is to acknowledge any financial interest or benefit that has
`
`arisen from the direct applications of your research. Further guidance on what is a conflict
`
`of interest and how to disclose it.
`
`8. Geolocation information. Submitting a geolocation information section, as a separate
`
`paragraph before your acknowledgements, means we can index your paper's study area
`
`accurately in JournalMap's geographic literature database and make your article more
`
`discoverable to others. More information.
`
`9. Data Availability Statement. If there is a data set associated with the paper, please
`
`provide information about where the data supporting the results or analyses presented in
`
`the paper can be found. Where applicable, this should include the hyperlink, DOI or other
`
`persistent identifier associated with the data set(s). Templates are also available to support
`
`authors.
`
`10. Data deposition. If you choose to share or make the data underlying the study open,
`
`please deposit your data in a recognized data repository prior to or at the time of
`
`submission. You will be asked to provide the DOI, pre-reserved DOI, or other persistent
`
`identifier for the data set.
`
`11. Supplemental online material. Supplemental material can be a video, dataset, fileset,
`
`sound file or anything which supports (and is pertinent to) your paper. We publish
`
`https://www.tandfonline.com/action/authorSubmission?journalCode=iedd20&page=instructions&
`
`5/13
`
`Sanofi Exhibit 2224.005
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`10/7/2019
`
`Expert Opinion on Drug Delivery
`
`supplemental material online via Figshare. Find out more about supplemental material and
`
`how to submit it with your article.
`
`12. A maximum of five figures. Figures should be high quality (1200 dpi for line art, 600 dpi for
`
`grayscale and 300 dpi for colour). Figures should be saved as TIFF, PostScript or EPS files.
`
`13. A maximum of five tables. Tables should present new information rather than duplicating
`
`what is in the text. Readers should be able to interpret the table without reference to the
`
`text. Please supply editable files.
`
`14. Equations. If you are submitting your manuscript as a Word document, please ensure that
`
`equations are editable. More information about mathematical symbols and equations.
`
`15. Units. Please use SI units (non-italicized).
`
`Using third-party material in your paper
`
`You must obtain the necessary permission to reuse third-party material in your article. The
`
`use of short extracts of text and some other types of material is usually permitted, on a
`
`limited basis, for the purposes of criticism and review without securing formal permission.
`
`If you wish to include any material in your paper for which you do not hold copyright, and
`
`which is not covered by this informal agreement, you will need to obtain written permission
`
`from the copyright owner prior to submission. More information on requesting permission
`
`to reproduce work(s) under copyright.
`
`Financial and competing interests disclosure
`
`Please include a disclosure of interest statement, using the subheading "Financial and
`
`competing interests disclosure." If you have no interests to declare, please state this
`
`(suggested wording: The authors report no conflicts of interest). For all NIH/Wellcome-
`
`funded papers, the grant number(s) must be included in the disclosure of interest
`
`statement. Read more on disclosing conflicts of interest.
`
`Clinical Trials Registry
`
`In order to be published in a Taylor & Francis journal, all clinical trials must have been
`
`registered in a public repository at the beginning of the research process (prior to patient
`
`enrolment). Trial registration numbers should be included in the abstract, with full details
`
`in the methods section. The registry should be publicly accessible (at no charge), open to all
`
`prospective registrants, and managed by a not-for-profit organization. For a list of registries
`
`that meet these requirements, please visit the WHO International Clinical Trials Registry
`
`https://www.tandfonline.com/action/authorSubmission?journalCode=iedd20&page=instructions&
`
`6/13
`
`Sanofi Exhibit 2224.006
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`10/7/2019
`
`Expert Opinion on Drug Delivery
`
`Platform (ICTRP). If your country does not require registration, you can still register your
`
`trial with http://clinicaltrials.gov/ or https://www.clinicaltrialsregister.eu/. The registration of
`
`all clinical trials facilitates the sharing of information among clinicians, researchers, and
`
`patients, enhances public confidence in research, and is in accordance with the ICMJE
`
`guidelines.
`
`Complying with ethics of experimentation
`
`Please ensure that all research reported in submitted papers has been conducted in an
`
`ethical and responsible manner, and is in full compliance with all relevant codes of
`
`experimentation and legislation. All papers which report in vivo experiments or clinical
`
`trials on humans or animals must include a written statement in the Methods section. This
`
`should explain that all work was conducted with the formal approval of the local human
`
`subject or animal care committees (institutional and national), and that c► inical trials have
`
`been registered as legislation requires. Authors who do not have formal ethics review
`
`committees should include a statement that their study follows the principles of the
`
`Declaration of Helsinki.
`
`Consent
`
`All authors are required to follow the ICMJE requirements on privacy and informed consent
`
`from patients and study participants. Please confirm that any patient, service user, or
`
`participant (or that person's parent or legal guardian) in any research, experiment, or
`
`clinical trial described in your paper has given written consent to the inclusion of material
`
`pertaining to themselves, that they acknowledge that they cannot be identified via the
`
`paper; and that you have fully anonymized them. Where someone is deceased, please
`
`ensure you have written consent from the family or estate. Authors may use this Patient
`
`Consent Form, which should be completed, saved, and sent to the journal if requested.
`
`Health and safety
`
`Please confirm that all mandatory laboratory health and safety procedures have been
`
`complied with in the course of conducting any experimental work reported in your paper.
`
`Please ensure your paper contains all appropriate warnings on any hazards that may be
`
`involved in carrying out the experiments or procedures you have described, or that may be
`
`involved in instructions, materials, or formulae.
`
`hups://www.tandfonline.corn/action/authorSubmission?journalCode=iedd20&page=instructions&
`
`7/13
`
`Sanofi Exhibit 2224.007
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`10/7/2019
`
`Expert Opinion on Drug Delivery
`
`Please include all relevant safety precautions; and cite any accepted standard or code of
`
`practice. Authors working in animal science may find it useful to consult the International
`
`Association of Veterinary Editors' Consensus Author Guidelines on Animal Ethics and
`
`Welfare and Guidelines for the Treatment of Animals in Behavioural Research and
`
`Teaching. When a product has not yet been approved by an appropriate regulatory body
`
`for the use described in your paper, please specify this, or that the product is still
`
`investigational.
`
`Submitting your paper
`
`The Expert Collection uses ScholarOne Manuscripts to manage the peer-review process. If
`
`you haven't submitted a paper to this journal before, you will need to create an account in
`
`the submission centre. Please read these guidelines and then submit your paper in the
`
`relevant Author Centre, where you will find user guides and a helpdesk.
`
`This Expert Collection journal accepts article proposals and presubmission enquiries via
`
`direct email to the editorial team. Please read these guidelines and then submit your paper
`
`to the Commissioning Editor. Please see our contacts page for details.
`
`Please note that this Expert Collection journal uses CrossrefrM to screen papers for
`
`unoriginal material. By submitting your paper to Expert Opinion on Drug Deliveryyou are
`
`agreeing to originality checks during the peer-review and production processes.
`
`On acceptance, we recommend that you keep a copy of your Accepted Manuscript. Find out
`
`more about sharing your work.
`
`Data Sharing Policy
`
`This journal applies the Taylor & Francis Basic Data Sharing Policy. Authors are encouraged
`
`to share or make open the data supporting the results or analyses presented in their paper
`
`where this does not violate the protection of human subjects or other valid privacy or
`
`security concerns.
`
`Authors are encouraged to deposit the dataset(s) in a recognized data repository that can
`
`mint a persistent digital identifier, preferably a digital object identifier (DOI) and recognizes
`
`https://www.tandfonline.com/action/authorSubmission?journalCode=iedd20&page=instructions&
`
`8/13
`
`Sanofi Exhibit 2224.008
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`10/7/2019
`
`Expert Opinion on Drug Delivery
`
`a long-term preservation plan. If you are uncertain about where to deposit your data,
`
`please see this information regarding repositories.
`
`Authors are further encouraged to cite any data sets referenced in the article and provide a
`
`Data Availability Statement.
`
`At the point of submission, you will be asked if there is a data set associated with the paper.
`
`If you reply yes, you will be asked to provide the DOI, pre-registered DOI, hyperlink, or
`
`other persistent identifier associated with the data set(s). If you have selected to provide a
`
`pre-registered DOI, please be prepared to share the reviewer URL associated with your
`
`data deposit, upon request by reviewers.
`
`Where one or multiple data sets are associated with a manuscript, these are not formally
`
`peer reviewed as a part of the journal submission process. It is the author's responsibility
`
`to ensure the soundness of data. Any errors in the data rest solely with the producers of
`
`the data set(s).
`
`Publication charges
`
`For invited content there are no submission fees or page charges for this journal.
`
`Color figures will be reproduced in color in your online article free of charge. If it is
`
`necessary for the figures to be reproduced in color in the print version, a charge will apply.
`
`Charges for color figures in print are £300 per figure ($400 US Dollars; $500 Australian
`
`Dollars; €350). For more than 4 color figures, figures 5 and above will be charged at £50 per
`
`figure ($75 US Dollars; $100 Australian Dollars; €65). Depending on your location, these
`
`charges may be subject to local taxes.
`
`FastTrack and RapidTrack publication
`
`All publications in Expert Opinion on Drug Deliveryare driven entirely by editorial
`
`considerations, and independent peer review. As part of the journal's responsive approach
`to the publication of timely research results, Expert Opinion on Drug Deliveryoffers an
`
`optional, prioritized Fast Track publication for unsolicited articles.
`
`https://www.tandfonline.corn/action/authorSubmission?journalCode=iedd20&page=instructions&
`
`9/13
`
`Sanofi Exhibit 2224.009
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`10/7/2019
`
`Expert Opinion on Drug Delivery
`
`We have the following service options from which you can choose:
`
`FastTrack:
`
`• Overall submission to online publication in 3-5 weeks.
`
`• Peer review comments within 1-2 weeks.
`
`• Publication support fee based on a charge of $7000/€6200/£5500 per article.
`
`RapidTrack:
`
`• Overall submission to online publication in 7-9 weeks.
`
`• Peer review comments in 3-4 weeks.
`
`• Publication support fee of $3900/€3400/9000 per article.
`
`StandardTrack:
`
`• Still a responsive and competitively rapid service.
`
`• Overall submission to online publication within 14-16 weeks.
`
`• Peer review comments in 8 weeks.
`
`Please note that all manuscripts (irrespective of the service chosen) are subject to strict and
`
`rigorous peer review. Acceptance for publication is solely dependent on the peer-review
`
`outcome.
`
`If you would like to discuss or select Fast Track publication, please contact the
`
`Commissioning Editor before, or on the day of, submission. Please see our contacts page
`
`for our Commissioning Editors' details.
`
`Copyright options
`
`Copyright allows you to protect your original material, and stop others from using your
`
`work without your permission. Taylor & Francis offers a number of different license and
`
`reuse options, including Creative Commons licenses when publishing open access. Read
`
`more on publishing agreements.
`
`Complying with funding agencies
`
`https://www.tandfonline.com/action/authorSubmission?journalCode=iedd20&page=instructions&
`
`10/13
`
`Sanofi Exhibit 2224.010
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`10/7/2019
`
`Expert Opinion on Drug Delivery
`
`We will deposit all National Institutes of Health or Wellcome Trust-funded papers into
`
`PubMedCentral on behalf of authors, meeting the requirements of their respective open
`
`access (OA) policies. If this applies to you, please tell our production team when you receive
`
`your article proofs, so we can do this for you. Check funders' OA policy mandates here. Find
`
`out more about sharing your work.
`
`Accepted Author Version (AAV)
`
`This Expert Collection journal publishes manuscripts online as rapidly as possible (3 days
`
`providing the copyright form has been received), as a PDF of the final, accepted (but
`
`unedited and uncorrected) paper. This is clearly identified as an unedited manuscript and is
`
`referred to as the Accepted Author Version (MV). No changes will be made to the content
`
`of the original paper for the AAV version but, after copy-editing, typesetting, and review of
`
`the resulting proof, the final corrected version (the Version of Record [VoR]), will be
`
`published, replacing the MV version.
`
`The VoR is the article version that will appear in an issue of the journal. Both the MV
`
`version and VoR can be cited using the same DOI (digital object identifier). To ensure rapid
`
`publication, we ask you to return your signed publishing agreement as quickly as possible,
`
`and return corrections within 48 hours of receiving your proofs.
`
`My Authored Works
`
`On publication, you will be able to view, download and check your article's metrics
`
`(downloads, citations and Altmetric data) via My Authored Works on Taylor & Francis
`
`Online. This is where you can access every article you have published with us, as well as
`
`your free eprints link, so you can quickly and easily share your work with friends and
`
`colleagues.
`
`We are committed to promoting and increasing the visibility of your article. Here are some
`
`tips and ideas on how you can work with us to promote your research.
`
`Article reprints
`
`You will be sent a link to order article reprints via your account in our production system.
`
`For enquiries about reprints, please contact the Taylor & Francis Author Services team at
`
`https://www.tandfonline.corn/action/authorSubmission?journalCode=iedd20&page=instructions&
`
`11/13
`
`Sanofi Exhibit 2224.011
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`10/7/2019
`
`Expert Opinion on Drug Delivery
`
`reprints@tandf.co.uk. You can also order print copies of the journal issue in which your
`
`article appears.
`
`Queries
`
`Should you have any queries, please visit our Author Services website or contact us here.
`
`Last updated 22-05-2018
`
`WITH THE EXPERT
`COLLECTION YOU CAN
`PUBLISH TIME SENSITIVE
`WORK IN AS LITTLE AS
`3 WEEKS
`
`EXPERT
`COLLECTION
`
`Good editing leads to
`a great manuscript
`
`hups://www.tandfonline.com/action/authorSubmission?journalCodei=iedd20&page=instructions&
`
`12/13
`
`Sanofi Exhibit 2224.012
`Mylan v. Sanofi
`IPR2018-01676
`
`

`

`10/7/2019
`
`Expert Opinion on Drug Delivery
`
`Information for
`
`Authors
`
`Editors
`
`Librarians
`
`Societies
`
`Help and info
`
`Help & contact
`
`Newsroom
`
`Commercial services
`
`Open access
`
`Overview
`
`Open journals
`
`Open Select
`
`Cogent OA
`
`Keep Lip tip date
`
`Registet to re.ceive ditirsonaltscid reseiticia and tost.iiiiastiat
`
`by em.i
`
`0 Sign me up
`
`ayo
`
`Copyright ID 2019 Inforrna UK Limited Privacy policy & cookies Terms & conditions
`
`Accessibility
`
`RE4tistered EitiOand W3ieS
`on SW"iP 15 ri,
`1-ioviiiick Place L
`
`https://www.tandfonline.com/action/authorSubmission?jountalCode=iedd20&page=instructions&
`
`13/13
`
`Sanofi Exhibit 2224.013
`Mylan v. Sanofi
`IPR2018-01676
`
`